Clinical trial
Biological Therapy in Treating Patients With Neuroblastoma That Has Not…
NCT00089258 · Memorial Sloan Kettering Cancer Center, Other · Completed
Key facts
| NCT number | NCT00089258 |
|---|---|
| Title | Biological Therapy in Treating Patients With Neuroblastoma That Has Not Responded to Previous Treatment |
| Official title | Phase II Study of Anti-GD2 3F8 Antibody and Biologic Response Modifiers for High-risk Neuroblastoma |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Neuroblastoma |
| Intervention type | Biological, Drug |
| Interventions | beta-glucan, monoclonal antibody 3F8, sargramostim, isotretinoin |
| Enrollment | 74 |
| Start date | Jul 1, 2004 |
| Primary completion | Nov 1, 2006 |
| First posted | Aug 5, 2004 |
| Last update posted | Jan 17, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: